Biogen tumbles after Medicare lays out Aduhelm coverage plan
Shares of Biogen slid Wednesday, a day after federal regulators slapped coverage limitations on the drugmaker's new Alzheimer's disease treatment.
Shares of Biogen slid Wednesday, a day after federal regulators slapped coverage limitations on the drugmaker's new Alzheimer's disease treatment.